PubMed Health⌕ Search

Biomedical subjects

Siamak Daneshmand

Publications and source records attributed to Siamak Daneshmand.

29 records · Page 2Linked to original sources
PubMed2003

Natural history of surgically treated bladder carcinoma with extravesical tumor extension.

BACKGROUND: The current TNM classification for bladder carcinoma stratifies extravesical extension into microscopic (pT3a) and macroscopic (pT3b) tumor involvement. The authors evaluated the outcomes of patients with pT3a and pT3b disease after radical cystectomy. METHODS: Patients (n = 129) with transitional cell carcinoma of the bladder treated with radical cystectomy alone demonstrated pathologic extravesical tumor extension: 37 (29%) had pT3a disease and 92 (71%) had pT3b disease. No patient received any adjuvant therapy. With a median follow-up of 13.6 years, the presence of lymph node involvement, margin positivity, local (pelvic) and distant disease recurrence, and clinical outcomes were determined. RESULTS: Of the 129 patients, 43 (33%) had lymph node tumor involvement: 13 of 37 patients with pT3a disease (35%) and 30 of 92 patients with pT3b disease (33%). The 10-year recurrence-free and overall survival for the entire group was 54% and 20%, respectively. No statistical difference between pT3a and pT3b disease was observed with regard to recurrence-free (P = 0.54) and overall (P = 0.66) survival. Lymph node involvement was predictive of a significantly worse 10-year recurrence-free survival (32%) compared with lymph node-negative disease (60%; P = 0.003). Local disease recurrence was reported to occur in 12 patients (9%), whereas 37 patients (29%) were reported to develop distant metastases. Among those who had disease recurrence, the type of disease recurrence (local or distant) was not found to be associated with tumor stage (pT3a vs, pT3b, P = 0.47). CONCLUSIONS: This cohort of surgically managed patients provided insight into the long-term natural history of pathologically confirmed extravesical bladder carcinoma after radical cystectomy. There was no important difference in the incidence of lymph node involvement, survival rates, and disease recurrence rates between patients with microscopic and macroscopic extravesical extension. Adjuvant protocols should be undertaken for these high-risk patients to further improve on these clinical outcomes.

Adult↗
PubMed2003

Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience.

BACKGROUND: The efficacy and long-term results of endoscopic management of upper tract transitional cell carcinoma (TCC) were examined. The authors evaluated the accuracy of endoscopic biopsy in determining tumor grade in the subset of patients who underwent open surgical excision. METHODS: Between 1987 and 2001, 50 patients (17 with a solitary kidney) underwent ureteroscopy and biopsy of upper tract TCC. Eleven patients underwent ureterectomy or nephroureterectomy shortly after endoscopic biopsy. There was no follow-up for nine patients. Thirty patients underwent endoscopic ablation of their primary tumor with laser or electrofulguration at the time of the initial biopsy and were followed with close endoscopic surveillance at 3-4-month intervals. RESULTS: For the 30 patients who underwent endoscopic ablation, mean follow-up was 38 months (range, 4-106 months). There was an average of 3.4 recurrences, with an average time to first recurrence of 7 months. Ten of the 30 patients underwent open resection during follow-up. Six patients exhibited tumor progression at follow-up. During the follow-up period, one patient died of recurrent disease, and six died of other causes. Endoscopic biopsy accurately predicted the tumor grade for 8 of the 9 patients who had open tumor resection within 2 months of their last biopsy and for 10 of the 11 patients who had open resection shortly after their initial endoscopic biopsy (overall accuracy, 18 of 20 [90%]). CONCLUSIONS: Endoscopic treatment of focal low-grade TCC of the upper urinary tract is feasible and safe, provided that vigilant follow-up and endoscopic surveillance are performed. Endoscopic biopsy provides accurate information regarding tumor grade.

Adult↗
PubMed2003

Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence.

PURPOSE: An incompetent urethral sphincter can be a significant factor contributing to urinary incontinence in patients with neurogenic bladders. We review our experience with 12 men who underwent a puboprostatic sling. MATERIALS AND METHODS: The study included 12 men (mean age 37.1 years) with neurogenic bladder due to spinal cord injury in 9 and spina bifida in 3. All patients were diagnosed with urethral incompetence based on fluorourodynamic evaluation. Medical therapy failed in all 12 patients and all complained of urine leakage with activity. All patients underwent placement of an autologous fascial sling distal to the prostatic urethra via an abdominal approach. Ten patients also underwent simultaneous bladder augmentation to correct high intravesical pressures. RESULTS: Followup ranged from 1 to 39 months (average 14.25). All patients manage the bladder with intermittent catheterization. Of the patients 8 are completely dry between catheterizations and 2 had significant improvement with only minimal leakage (1 pad per day), with an overall success rate of 83%. One patient improved initially but subsequently underwent placement of an artificial urinary sphincter for residual stress incontinence. In 1 patient several external sphincterotomies failed despite adequate sling placement. There were no complications related to the placement of the sling and all patients are able to perform intermittent catheterization without difficulty. CONCLUSIONS: In select male patients the puboprostatic sling can be an effective and safe method to treat urethral incompetence secondary to neurogenic voiding dysfunction.

Adult↗
PubMed2003

Benign retroperitoneal schwannoma: a case series and review of the literature.

OBJECTIVES: To present our experience with four retroperitoneal schwannomas treated by surgical excision and review the current literature. Retroperitoneal schwannomas are rare, benign tumors and infrequently present to the urologist. METHODS: From 1997 through 2002, the charts of 164 patients with a diagnosis of benign retroperitoneal soft tissue mass were reviewed. Of those, four had a pathologic diagnosis of retroperitoneal schwannoma. RESULTS: Three of the 4 patients were women, with a median age of 54 years (range 46 to 80). The average tumor size was 13.7 cm (range 8.8 to 20). All patients underwent magnetic resonance imaging, computed tomography, or ultrasonography, and 3 of the 4 patients underwent a computed tomography-guided fine needle aspiration biopsy (all were either inaccurate or inconclusive). All patients underwent complete tumor excision with free margins of resection and tolerated surgery without any complications. None of the patients have had any evidence of recurrence at a mean follow-up of 26 months (range 10 to 48). CONCLUSIONS: Retroperitoneal schwannomas are difficult to diagnose preoperatively. Computed tomography-guided fine needle aspiration biopsy does not appear to provide an accurate preoperative diagnosis. The surgical approach should focus on complete excision of the mass. Patients undergoing complete surgical resection tend to do well without evidence of early recurrence.

Aged↗
PubMed2002

Endoscopic management of renal hemangioma.

PURPOSE: Renal hemangioma is a rare clinical entity that is difficult to diagnose. In the past it was treated with partial or complete nephrectomy. However, in the age of minimally invasive procedures endoscopy has enabled more accurate diagnosis and management. We reviewed our experience with transurethral ureterorenoscopy using a flexible ureteroscope to determine the feasibility and success of endoscopic treatment of renal hemangioma. MATERIALS AND METHODS: We reviewed the records of 15 patients with a mean age of 37.5 years who presented with recurrent lateralized gross hematuria and were diagnosed with renal hemangioma based on transurethral ureterorenoscopy using a flexible ureteroscope. Lesions were treated using a 2 or 3Fr electrocautery probe, or a 200 mu. laser fiber with holmium or neodymium:YAG energy. RESULTS: Followup was 2 to 96 months (mean 20.2). Of the 15 cases 14 were successfully managed by endoscopy. A single patient initially treated with endoscopy in 1988 underwent partial nephrectomy shortly thereafter secondary to continued bleeding. No patient had any complication related to the procedure. All except 1 of the 12 patients on whom followup data were available remain free of any hematuria. CONCLUSIONS: When the source of unilateral hematuria is unknown or in doubt, particularly in young patients, the diagnosis of a hemangioma should be considered. Transurethral ureterorenoscopy using a flexible ureteroscope is an excellent method of visualizing the offending lesion and safely treating it using an electrocautery probe or laser fiber.

Adolescent↗
PubMedDate not supplied

Current clinical trials in renal cell carcinoma.

The treatment of renal cell carcinoma remains primarily surgical. Consequently, it is not surprising that urologists have been active in the design and operation of clinical trials for patients with kidney cancer. Currently, clinical trial efforts of the urologic community are focused on the adjuvant setting in patients undergoing nephrectomy at high risk for recurrence or metastasis. As newer agents become available and are applied earlier during the course of the disease, the involvement of urologists in clinical trials in renal cell carcinoma will increase. This review highlights several key trials currently available for patients with kidney cancer.

Carcinoma, Renal Cell↗